ARTEMICAFE IN WOMEN WITH ADVANCED OVARIAN CANCER
PHASE 1 DOSE ESCALATION
“‘This trial represents an important step in exploring how Artemisia annua might help patients with ovarian cancer after they complete standard treatments,’ said Frederick Ueland, M.D., a gynecologic oncologist with the UK Markey Cancer Center and study investigator.”
“Finding a well-tolerated maintenance therapy that could potentially delay or prevent recurrence would be transformative for ovarian cancer care.”
INDEPENDENT CLINICAL TRIAL:
Patients with stage II-IV, age >/= 18, achieved a complete or partial response to any line of chemotherapy.
Safe to drink up to
4 times a day
No patient experienced a dose limiting toxicity
Active Phase 2 maintenance therapy trial for prostate cancer patients
